Stockwinners Market Radar for March 12, 2025 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:49 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1) The Department of Justice, DOJ, dropped a proposal to force Alphabet's Google (GOOGL) to sell its investments in AI companies to boost competition in online search, Jody Godoy of Reuters reports. 2) A federal judge certified a class action accusing Boeing (BA) of prioritizing profit over safety and overstating its commitment to safe aircraft prior to the January 2024 mid-air cabin panel blowout, Reuters reports. 3) Kantar is set to be broken up and sold by Bain (BCSF) and WPP (WPP), Ivan Levingston and Daniel Thomas of The Financial Times reports. 4) Baidu (BIDU) announced the pricing of its $2B in aggregate principal amount of exchangeable bonds due 2032. 5) Jefferies analyst Linda Tsai upgraded MAA (MAA) to Buy from Hold with a price target of $190, up from $148.

18:34 EDT Alumis announces data from the OLE of its Phase 2 STRIDE trial - Alumis announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque psoriasis. The results were presented during a late-breaking session at the 2025 American Academy of Dermatology Association, AAD, Annual Meeting in Orlando, Florida. These data demonstrated that patients receiving 40 mg twice daily dosing of ESK-001 achieved long-term sustained or increasing clinical responses through Week 52 compared to Week 12 as measured by PASI 90, PASI 100, and sPGA 0. At Week 52, patients maintained robust clinical improvements in control of itch and quality-of-life. Treatment with ESK-001 continued to be generally well tolerated at week 52, with safety and tolerability consistent with previously reported Week 16 and Week 28 data and no new safety findings.

18:29 EDT Incyte, Eli Lilly present results from Phase 3 BRAVE-AA-PEDS study - Late-breaking results from Eli Lilly and Company (LLY) and Incyte (INCY) found adolescent patients with severe alopecia areata, AA, treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36. Findings from the Phase 3 BRAVE-AA-PEDS study were presented in a late-breaker presentation at the American Academy of Dermatology, AAD Annual Meeting taking place March 7-11 in Orlando. At Week 36: 60.0% of patients receiving baricitinib 4 mg and 36.9% of patients receiving baricitinib 2 mg saw at least a 50% improvement in their disease compared to 5.7% on placebo. 42.4% of patients receiving baricitinib 4 mg and 27.4% of patients receiving baricitinib 2 mg achieved 80% or more scalp hair coverage, compared to 4.5% on placebo. 36.5% of patients receiving baricitinib 4 mg and 21.4% of patients receiving baricitinib 2 mg had 90% or more scalp hair coverage, compared to 2.3% on placebo. 50.0% of patients receiving baricitinib 4 mg and 24.1% of patients receiving baricitinib 2 mg achieved significant eyebrow regrowth compared to 0% on placebo. 42.9% of patients receiving baricitinib 4 mg achieved significant eyelash regrowth, and 25.5% receiving baricitinib 2 mg saw improved eyelash regrowth, compared to 14.0% on placebo.

18:25 EDT Johnson & Johnson announces new icotrokinra data from Phase 3 program - Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis, PsO, seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab. Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor and is being studied in adults and adolescents 12 years of age and older with moderate-to-severe plaque PsO.

18:21 EDT InnoCare Pharma announces the data of TYK2 inhibitor ICP-488 - InnoCare Pharma announced that the data of the novel TYK2 inhibitor ICP-488 developed by the Company for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 American Academy of Dermatology, AAD, Annual Meeting as a late-breaking oral presentation. The study results demonstrated that ICP-488 is highly effective in treating psoriasis patients at both 6 mg QD and 9 mg QD doses. Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients. A total of 129 psoriasis patients were randomized into three groups to receive once daily oral doses of ICP-488 at 6 mg, 9 mg, or placebo for twelve weeks. The primary endpoint was the percentage of subjects who achieved at least a 75% improvement from baseline in the Psoriasis Area and Severity Index score at week 12.

18:19 EDT Bristol Myers announces data from Phase 3 POETYK PsA-2 - Bristol Myers Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. The POETYK PsA-2 trial met its primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving ACR20 response compared with placebo at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment was consistent with that established in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials. Additionally, treatment with Sotyktu met important secondary endpoints across PsA disease activity at Week 16, demonstrating improvement across clinical signs and symptoms, extra-articular manifestations and patient-reported outcomes. Significantly more Sotyktu-treated patients achieved a Psoriasis Area and Severity Index 75 response compared with placebo.